Brief: Takeda Says Zasocitinib Significantly Outperforms Deucravacitinib In Head-To-Head Phase 3 Psoriasis Study
BRIEF-Takeda Says Zasocitinib Significantly Outperforms Deucravacitinib In Head-To-Head Phase 3 Psoriasis Study June 11 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:
TAKEDA PHARMACEUTICAL: ZASOCITINIB SIGNIFICANTLY OUTPERFORMS DEUCRAVACITINIB IN HEAD-TO-HEAD PHASE 3 PSORIASIS STUDY
TAKEDA: MORE THAN 35% ZASOCITINIB-TREATED PATIENTS ACHIEVED COMPLETE SKIN CLEARANCE AT WEEK 16, MORE THAN 2.5 TIMES RESPONSE RATE FOR DEUCRAVACITINIB
TAKEDA: ONCE-DAILY ORAL ZASOCITINIB DEMONSTRATED STATISTICAL SUPERIORITY OVER DEUCRAVACITINIB FOR ALL PRIMARY, KEY SECONDARY ENDPOINTS IN STUDY
TAKEDA: ZASOCITINIB WAS GENERALLY WELL TOLERATED WITH A CONSISTENT SAFETY TOLERABILITY PROFILE; NO NEW SAFETY SIGNALS IDENTIFIED
TAKEDA: ON TRACK TO SUBMIT NEW DRUG APPLICATION FOR PLAQUE PSORIASIS WITH US FDA, OTHER REGULATORY AUTHORITIES STARTING THIS FISCAL YEAR
Source text: [ID:]
Further company coverage: 4502.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom (updated)